Elastase作为靶点在铜绿假单胞菌眼科感染治疗中的研究进展  

Research progress on Elastase as a therapeutic target for Pseudomonas aeruginosa ophthalmic infection

作　　者：李晔 胡沁媛 周敏[1] 王聪尧 李健(综述)[2] 万鹏霞(审校) LI Ye;HU Qinyuan;ZHOU Min;WANG Congyao;LI Jian;WAN Pengxia(Department of Ophthalmology,First Affiliated Hospital of Sun Yat-Sen University,Guangzhou 510080,China;Department of Otolaryngology,First Affiliated Hospital of Sun Yat-Sen University,Guangzhou 510080,China)

机构地区：[1]中山大学附属第一医院眼科,广州510080 [2]中山大学附属第一医院耳鼻喉科,广州510080

出　　处：《眼科学报》2020年第3期186-191,共6页Eye Science

基　　金：国家药监局合作课题(K0601300);广东省药学会基金(2019QX16)。

摘　　要：铜绿假单胞菌性角膜炎破坏力强、致盲率高。随着“后抗生素时代”的到来,新的抗铜绿假单胞菌感染药物的研究迫在眉睫。抗毒力因子药物可选择性地遏制细菌的毒素表达、细菌黏附和免疫逃避,在不影响细菌生长的前提下可降低细菌的毒性,具有巨大的研究前景。弹性蛋白酶(Elastase)是铜绿假单胞菌中一种主要的毒力因子,Elastase抑制剂可有效降低铜绿假单胞菌的致病力,帮助人体免疫系统有效清除病原菌,是一种非常有前景的治疗策略。本文综述了铜绿假单胞菌Elastase及其抑制剂的研究进展,为治疗铜绿假单胞菌眼科感染的新方法研究提供理论依据。With the advent of the“post-antibiotic era”,the research on new anti-Pseudomonas aeruginosa infection drugs is urgent.Anti-virulence factor drugs can selectively inhibit the toxin expression,bacterial adhesion and immune avoidance of bacteria,and reduce the toxicity of bacteria without affecting the growth of bacteria,which has a promising research prospect.Elastase is the main virulence factor of Pseudomonas aeruginosa,and Elastase inhibitors can effectively mitigate the toxicity of Pseudomonas aeruginosa,assist the body’s immune system to eliminate pathogen effectively,which is a promising therapeutic strategy.In this article,the research progress on the Pseudomonas aeruginosa Elastase and its inhibitors was reviewed,providing theoretical basis for the research of new therapeutic strategies of Pseudomonas aeruginosa ophthalmic infection.

关 键 词：弹性蛋白酶 铜绿假单胞杆菌 毒力因子 

分 类 号：R771[医药卫生—眼科]